United Therapeutics Corporation (UTHR) Receives Hold Rating from Cowen and Company

United Therapeutics Corporation (NASDAQ:UTHR)‘s stock had its “hold” rating reiterated by research analysts at Cowen and Company in a research note issued to investors on Friday, October 27th. They presently have a $129.00 target price on the biotechnology company’s stock. Cowen and Company’s price objective would indicate a potential upside of 7.72% from the stock’s current price.

A number of other analysts have also commented on UTHR. UBS AG reissued a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. Jefferies Group LLC restated a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research note on Friday, July 14th. Finally, BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $132.82.

United Therapeutics Corporation (NASDAQ:UTHR) opened at $119.75 on Friday. The company has a market capitalization of $5,170.00, a PE ratio of 10.67 and a beta of 1.38. United Therapeutics Corporation has a twelve month low of $112.01 and a twelve month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The business had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. During the same period in the previous year, the company posted $4.23 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. equities research analysts predict that United Therapeutics Corporation will post 11.92 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Receives Hold Rating from Cowen and Company” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2017/11/15/united-therapeutics-corporations-uthr-hold-rating-reiterated-at-cowen-and-company.html.

In related news, Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total value of $77,998.40. Following the transaction, the director now owns 3,295 shares of the company’s stock, valued at $443,111.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,260 shares of the stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $121.46, for a total value of $153,039.60. Following the completion of the transaction, the chief executive officer now directly owns 1,400 shares in the company, valued at approximately $170,044. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,053 shares of company stock worth $2,234,661. Insiders own 7.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Stifel Financial Corp boosted its holdings in shares of United Therapeutics Corporation by 49.1% during the first quarter. Stifel Financial Corp now owns 3,073 shares of the biotechnology company’s stock worth $412,000 after purchasing an additional 1,012 shares during the period. OppenheimerFunds Inc. boosted its holdings in shares of United Therapeutics Corporation by 24.8% during the first quarter. OppenheimerFunds Inc. now owns 2,881 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 573 shares during the period. Teachers Advisors LLC boosted its holdings in shares of United Therapeutics Corporation by 17.0% during the first quarter. Teachers Advisors LLC now owns 91,328 shares of the biotechnology company’s stock worth $12,364,000 after purchasing an additional 13,239 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of United Therapeutics Corporation by 4.8% during the first quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 95 shares during the period. Finally, Thrivent Financial For Lutherans boosted its holdings in shares of United Therapeutics Corporation by 16.4% during the first quarter. Thrivent Financial For Lutherans now owns 8,430 shares of the biotechnology company’s stock worth $1,141,000 after purchasing an additional 1,190 shares during the period.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply